HONG KONG, Aug. 30, 2014 /PRNewswire/ — Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has …
Read MoreTag: PHA
Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS
— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study
OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the …
Read MoreCPhI & P-MEC China 2014 Event Achieved its Grand Closing
Leading Global Industry Trends, Lighting up the China Pharmaceutical Dream
 |
SHANGHAI, Aug. 26, 2014 /PRNewswire/ — CPhI, ICSE & BioPh China 2014 and P-MEC, InnoPack & LABWorld China 2014, held on 26th -28th of June hosted by …
Read MoreViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
LONDON, Aug. 23, 2014 /PRNewswire/ — ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is …
Read MoreAmerigen Pharmaceuticals Ltd. Announces that its Chinese Subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has Received Chinese FDA (CFDA) Approval and has Subsequently Launched its Generic Mecobalamin 0.5 mg Tablets into the China Domestic Market
LYNDHURST, N.J., Aug. 20, 2014 /PRNewswire/ — Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic market. …
Read MoreCoherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
— Company To Pursue Next Stage of Development
REDWOOD CITY, California, Aug. 15, 2014 /PRNewswire/ — Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic …
Read MoreMundipharma Announces Principal Partner Sponsorship for Singapore’s National Day Parade 2014
SINGAPORE, Aug. 7, 2014 /PRNewswire/ — Mundipharma, one of the fastest growing pharmaceutical companies in the region, announced today its status as principal partner of this year’s National Day Parade (NDP) — the first time ever for a pharmaceutical company …
Read MoreFrost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
–The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs
MOUNTAIN VIEW, Calif., Aug. 5, 2014 /PRNewswire/ — Based on its recent …
Read More